This website is intended for US Healthcare Professionals FOR US PATIENTS »

The NAVIGATOR Reimbursement and Access Program®

The NAVIGATOR Program is a support program that may help give more of your patients access to PRIALT.

Identifies ways that may help patients minimize out-of-pocket expenses for PRIALT

Helps determine insurance coverage and explores financial options prior to placing an order

Provides direct, personal access to a trained specialist who can answer questions and help guide you through the process

Learn more about how to use the NAVIGATOR Program.
Access forms and other resources available for download.

support is available.

Call the NAVIGATOR Program at
1.855.PRIALT1 (774.2581)

WARNING: NEUROPSYCHIATRIC ADVERSE REACTIONS PRIALT® (ziconotide) intrathecal infusion is contraindicated in patients with a preexisting history of psychosis. Severe psychiatric symptoms and neurological impairment may occur during treatment with PRIALT. Monitor all patients frequently for evidence of cognitive impairment, hallucinations, or changes in mood or consciousness. Discontinue PRIALT therapy in the event of serious neurological or psychiatric signs or symptoms.


PRIALT is indicated for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine.


PRIALT is contraindicated in patients with:

  • A known hypersensitivity to ziconotide or any of its formulation components.
  • Any other concomitant treatment or medical condition that would render IT administration hazardous, such as the presence of infection at the microinfusion injection site, uncontrolled bleeding diathesis, and spinal canal obstruction that impairs circulation of cerebrospinal fluid (CSF).
  • A pre-existing history of psychosis.

Advise patients of the signs and symptoms of meningitis, such as fever, headache, stiff neck, altered mental status, nausea, vomiting, and occasionally seizures. Reduced levels of consciousness and creatine kinase (CK) elevations have occurred in patients taking PRIALT. Monitor serum CK periodically. For patients being withdrawn from intrathecal opiates, gradually taper over a few weeks and replace with a pharmacologically equivalent dose of oral opiates.

The most frequently reported adverse reactions (≥25%) in clinical trials (n=1254 PRIALT-treated patients) were dizziness, nausea, confusional state, and nystagmus. Slower titration of PRIALT may result in fewer serious adverse reactions and discontinuations for adverse reactions.

PRIALT is not intended for intravenous (IV) administration. PRIALT is for use only in the Medtronic SynchroMed® II Infusion System and the CADD-Micro Ambulatory Infusion Pump.

Please see full Prescribing Information including BOXED Warning.